Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9HAU8

UPID:
RNPL1_HUMAN

ALTERNATIVE NAMES:
Arginyl aminopeptidase-like 1; Methionyl aminopeptidase

ALTERNATIVE UPACC:
Q9HAU8; Q5XKC3; Q6NX56; Q96AC9; Q9H033; Q9NVD0

BACKGROUND:
The enzyme Aminopeptidase RNPEPL1, with alternative names including Arginyl aminopeptidase-like 1 and Methionyl aminopeptidase, is recognized for its ability to preferentially hydrolyze N-terminal methionine, citrulline, or glutamine. This activity is essential for the proper processing and maturation of proteins, indicating its significant role in cellular functions.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Aminopeptidase RNPEPL1 offers a promising avenue for the development of novel therapeutic approaches. Its key role in protein processing underscores its potential relevance in disease mechanisms and treatment strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.